RESUMO
Under the background of innovation-driven development and advanced biopharmaceutical innovative construction,this paper selects the indicators from three aspects:capital investment,talent resources and innovation output,and a comparative evaluation of the innovation drug R&D ability of China and the developed countries namely United States,Japan and Europe,as the basis to reveal the policy causes of the innovation ability discrepancies in China.The empirical results show that the total amount of funds invested in R&D of innovative drugs is increasing and the number of R&D personnel has become the scale.However,the investment intensity is still far from that of the developed countries,and the capital investment structure is also deficient of rationality.This is inseparable from the absence of preferential taxation policies,lack of high-level personnel training,environmental defects in production and research,and narrow coverage of health insurance policies.
RESUMO
Under the background of innovation-driven development and advanced biopharmaceutical innovative construction,this paper selects the indicators from three aspects:capital investment,talent resources and innovation output,and a comparative evaluation of the innovation drug R&D ability of China and the developed countries namely United States,Japan and Europe,as the basis to reveal the policy causes of the innovation ability discrepancies in China.The empirical results show that the total amount of funds invested in R&D of innovative drugs is increasing and the number of R&D personnel has become the scale.However,the investment intensity is still far from that of the developed countries,and the capital investment structure is also deficient of rationality.This is inseparable from the absence of preferential taxation policies,lack of high-level personnel training,environmental defects in production and research,and narrow coverage of health insurance policies.
